← Leaderboards
William M Lee
University Of Pennsylvania
$5,600,205
Attributed
$7,143,860
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $734.4K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$7,143,860 · 8
By mechanism
R01$6,659,909 · 4
M01$483,951 · 3
U54$0 · 1
Top collaborators
- Keith T Flaherty5 shared
- Katherine L Nathanson5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Susan R Ross$18,891,931
- Jaquelin Page Dudley$7,427,251
- Wendy K Rathmell$9,818,166
- Mark I Greene$18,808,015
- Lewis A Chodosh$38,386,361
Others in their field
Top investigators on “Angiogenesis Inhibitors”
- Walter John Curran · Thomas Jefferson University$26,641,549
- David Heimbrook · Leidos Biomedical Research, Inc.$24,469,358
- David R Harder · Medical College Of Wisconsin$16,163,720
- Elizabeth Marion Jaffee · Johns Hopkins University$12,679,276
- Garrett M Brodeur · Children'S Hospital Of Philadelphia$12,442,187
- Erwin G Van Meir · University Of Alabama At Birmingham$11,726,130
Research focus
Angiogenesis InhibitorsLaboratory MouseAngiogenesisNeoplasm /Cancer Blood SupplyApoptosisCell ProliferationCombination Cancer TherapyDisease /Disorder ModelMalignant NeoplasmsBlood VesselsNeoplasms In Vascular TissueResponseResistanceBaseTumorClinical TrialsCharacteristicsNeoplastic GrowthHypoxiaPericytesNeoplasm /Cancer Radiation TherapyCarcinogenesisBreast NeoplasmsImmunocytochemistry
Grant awards (28)
Genotype and phenotype predictors in therapy response in renal cell carcinoma$421,339
R01 · FY2013 · CA · contact PI
Genotype and phenotype predictors in therapy response in renal cell carcinoma$447,222
R01 · FY2012 · CA · contact PI
Genotype and phenotype predictors in therapy response in renal cell carcinoma$449,030
R01 · FY2011 · CA · contact PI
Genotype and phenotype predictors in therapy response in renal cell carcinoma$489,269
R01 · FY2010 · CA · contact PI
Genotype and phenotype predictors in therapy response in renal cell carcinoma$508,622
R01 · FY2009 · CA · contact PI
Transgenic Mice as Models for Antivascular Therapy$334,388
R01 · FY2007 · CA · contact PI
Mechanisms of Tumor Rejection$188,460
R01 · FY2007 · CA · contact PI
HALT-C TRIAL$17,315
M01 · FY2007 · RR · contact PI
Transgenic Mice as Models for Antivascular Therapy$344,375
R01 · FY2006 · CA · contact PI
Mechanisms of Tumor Rejection$194,088
R01 · FY2006 · CA · contact PI
HALT-C TRIAL$101,844
M01 · FY2006 · RR · contact PI
Transgenic Mice as Models for Antivascular Therapy$352,663
R01 · FY2005 · CA
Mechanisms of Tumor Rejection$198,759
R01 · FY2005 · CA
HALT-C TRIAL$182,957
M01 · FY2005 · RR
Transgenic Mice as Models for Antivascular Therapy$352,663
R01 · FY2004 · CA
Mechanisms of Tumor Rejection$198,759
R01 · FY2004 · CA
HALT-C Trial$181,835
M01 · FY2004 · RR
Transgenic Mice as Models for Antivascular Therapy$352,663
R01 · FY2003 · CA
Mechanisms of Tumor Rejection$198,759
R01 · FY2003 · CA
Optical Imaging of Tumor Physiologic/ Metabolic Changes in Antiangiogenic Therapy$0
U54 · FY2003 · CA
MECHANISMS OF TUMOR REJECTION$254,282
R01 · FY2002 · CA
TUMOR PHYSIOLOGICAL EFFECTS OF ANGIOGENESIS INHIBITION$248,674
R01 · FY2002 · CA
TUMOR PHYSIOLOGICAL EFFECTS OF ANGIOGENESIS INHIBITION$283,982
R01 · FY2001 · CA
MECHANISMS OF TUMOR REJECTION$250,797
R01 · FY2001 · CA
TUMOR PHYSIOLOGICAL EFFECTS OF ANGIOGENESIS INHIBITION$39,972
R01 · FY2001 · CA
TUMOR PHYSIOLOGICAL EFFECTS OF ANGIOGENESIS INHIBITION$25,061
R01 · FY2001 · CA
TUMOR PHYSIOLOGICAL EFFECTS OF ANGIOGENESIS INHIBITION$278,672
R01 · FY2000 · CA
MECHANISMS OF TUMOR REJECTION$247,410
R01 · FY2000 · CA